---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-088701"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2026-08-13T11:56:27+00:00"
generated_at: "2026-08-13T12:00:08.524569+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bluejay completes SYMON-II enrollment of 750 patients; cash $9.6M, runway to Q2 2027

## Summary
- Completed targeted enrollment of 750 patients in SYMON-II pivotal study for Symphony IL-6 test.
- Cash and equivalents $9.6M at June 30, 2026 vs $5.2M at Dec 31, 2025; net proceeds $7.6M from June 2026 private placement.
- Signed US manufacturing contract to mitigate supply-chain risk; advancing toward FDA 510(k) submission.
- Cash estimated to fund operations through Q2 2027.

## SEC filing metadata
- accession: 0001213900-26-088701
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2026-08-13T11:56:27+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390026088701/0001213900-26-088701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390026088701/ea0301888-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-088701
- JSON: https://secwatch.observer/filing/0001213900-26-088701.json
- Plain text: https://secwatch.observer/filing/0001213900-26-088701.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.